261 related articles for article (PubMed ID: 16698182)
1. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy.
Rabik CA; Njoku MC; Dolan ME
Cancer Treat Rev; 2006 Jun; 32(4):261-76. PubMed ID: 16698182
[TBL] [Abstract][Full Text] [Related]
2. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
Cai Y; Wu MH; Xu-Welliver M; Pegg AE; Ludeman SM; Dolan ME
Cancer Res; 2000 Oct; 60(19):5464-9. PubMed ID: 11034089
[TBL] [Abstract][Full Text] [Related]
3. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
4. Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine.
Xu-Welliver M; Kanugula S; Pegg AE
Cancer Res; 1998 May; 58(9):1936-45. PubMed ID: 9581836
[TBL] [Abstract][Full Text] [Related]
5. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
[TBL] [Abstract][Full Text] [Related]
6. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine.
Loktionova NA; Xu-Welliver M; Crone TM; Kanugula S; Pegg AE
Biochem Pharmacol; 1999 Jul; 58(2):237-44. PubMed ID: 10423163
[TBL] [Abstract][Full Text] [Related]
7. Alteration of the conserved residue tyrosine-158 to histidine renders human O6-alkylguanine-DNA alkyltransferase insensitive to the inhibitor O6-benzylguanine.
Xu-Welliver M; Leitão J; Kanugula S; Pegg AE
Cancer Res; 1999 Apr; 59(7):1514-9. PubMed ID: 10197622
[TBL] [Abstract][Full Text] [Related]
8. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
Liu L; Schwartz S; Davis BM; Gerson SL
Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
[TBL] [Abstract][Full Text] [Related]
10. Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities.
Hansen RJ; Nagasubramanian R; Delaney SM; Cherian MM; Lin S; Kogan SC; Dolan ME
J Pharmacol Exp Ther; 2005 Dec; 315(3):1247-55. PubMed ID: 16126841
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
Gajewski TF; Sosman J; Gerson SL; Liu L; Dolan E; Lin S; Vokes EE
Clin Cancer Res; 2005 Nov; 11(21):7861-5. PubMed ID: 16278409
[TBL] [Abstract][Full Text] [Related]
12. O6-benzylguanine and its role in chemotherapy.
Dolan ME; Pegg AE
Clin Cancer Res; 1997 Jun; 3(6):837-47. PubMed ID: 9815757
[TBL] [Abstract][Full Text] [Related]
13. Role of codon 160 in the sensitivity of human O6-alkylguanine-DNA alkyltransferase to O6-benzylguanine.
Xu-Welliver M; Leitão J; Kanugula S; Meehan WJ; Pegg AE
Biochem Pharmacol; 1999 Oct; 58(8):1279-85. PubMed ID: 10487529
[TBL] [Abstract][Full Text] [Related]
14. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
Liu L; Markowitz S; Gerson SL
Cancer Res; 1996 Dec; 56(23):5375-9. PubMed ID: 8968088
[TBL] [Abstract][Full Text] [Related]
15. Point mutations in human O6-alkylguanine-DNA alkyltransferase prevent the sensitization by O6-benzylguanine to killing by N,N'-bis (2-chloroethyl)-N-nitrosourea.
Loktionova NA; Pegg AE
Cancer Res; 1996 Apr; 56(7):1578-83. PubMed ID: 8603405
[TBL] [Abstract][Full Text] [Related]
16. S-alkylthiolation of O6-methylguanine-DNA-methyltransferase (MGMT) to sensitize cancer cells to anticancer therapy.
Juillerat A; Juillerat-Jeanneret L
Expert Opin Ther Targets; 2007 Mar; 11(3):349-61. PubMed ID: 17298293
[TBL] [Abstract][Full Text] [Related]
17. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
Wedge SR; Porteous JK; Newlands ES
Br J Cancer; 1996 Oct; 74(7):1030-6. PubMed ID: 8855970
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of MGMT in the treatment of cancer.
Gerson SL
J Clin Oncol; 2002 May; 20(9):2388-99. PubMed ID: 11981013
[TBL] [Abstract][Full Text] [Related]
19. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model.
Wedge SR; Porteous JK; Newlands ES
Cancer Chemother Pharmacol; 1997; 40(3):266-72. PubMed ID: 9219512
[TBL] [Abstract][Full Text] [Related]
20. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.
Spiro TP; Gerson SL; Liu L; Majka S; Haaga J; Hoppel CL; Ingalls ST; Pluda JM; Willson JK
Cancer Res; 1999 May; 59(10):2402-10. PubMed ID: 10344750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
